Alzheimer DiseaseDEEPAMYNCT07309107
Deep Learning on Amyloid Positons Emission Tomography
An observational study of Alzheimer Disease, run by Central Hospital, Nancy, France at 3 sites in France.
Trial summary
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating… Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Alzheimer Disease
- How many people
- 40 participants
- Where
- 3 sitesFrance
- Study dates
- 6 May 2026to 30 Jan 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Adult, Older adult
Study population: Patients with objective cognitive impairment, referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, will be included
Who may be able to join
- Patients with objective cognitive impairment,
- Referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,
Who cannot join
- Patient have objected to the use of their data.
Trial locations and contacts
3 sites in 1 country. Contact the study team or a site near you to ask about taking part.
France3 sites, 3 recruiting
- Recruiting
CHRU NANCY Brabois, nuclear medicine department
Vandœuvre-lès-Nancy, 54511
Antoine AV VERGER, MD,PhD, 383154276 ext. +33, a.verger@chru-nancy.fr
Véronique VR ROCH, MsC, 383154276 ext. +33, v.roch@chru-nancy.fr
- Recruiting
Nancy's hospital
Vandœuvre-lès-Nancy, 54511
Antoine Verger, PhD
- Recruiting
Nuclear medicine department CHRU de NANCY Brabois
Vandœuvre-lès-Nancy, 54511
VERONIQUE ROCH, MSc, 0383154276 ext. +33, v.roch@chru-nancy.fr
About this study
Official title: Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of [18F]flutemetamol.
- Conditions
- Alzheimer Disease
- Medical subject headings
- Alzheimer Disease
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol.
Visual analysis of the cerebral [¹⁸F]flutemetamol PET images will be performed by two nuclear medicine specialists in a blinded manner, with a third reader acting as an arbitrator in case of disagreement, according to routine diagnostic criteria.
Measured: Day one
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2025
- Study start6 May 2026
- Primary completion20 Nov 2026 (estimated)
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Antoine VERGER, Central Hospital, Nancy, France
- Investigators
- Principal Investigator, Principal investigator, CHRU of NANCY
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07309107
- Sponsor's protocol ID
- 2025PI190
- Acronym
- DEEPAMY
- Status last verified
- Jun 2026
- First submitted
- 24 Nov 2025
- Last updated
- 25 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Deep Learning-Based Noise Reduction Algorithm on Visual Analysis and Centiloid Quantification in Reduced-Dose and, or Time Acquisition Amyloid PET Imaging
- ClinicalTrials.gov ID
- NCT07309107
- Acronym / sponsor ID
- DEEPAMY / 2025PI190
- Conditions
- Alzheimer Disease
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Central Hospital, Nancy, FranceUniversity, hospital or other
- Study start
- 6 May 2026 (actual)
- Primary completion
- 20 Nov 2026 (estimated)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 30 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Reducing injected dose and/or acquisition time in amyloid PET imaging would improve comfort, radiation safety and cost-effectiveness in diagnosis and follow-up of patients. This study evaluates the impact of a deep learning-based noise reduction algorithm on visual analysis and Centiloid quantification when simulating reduced injected doses of [18F]flutemetamol.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Patients with objective cognitive impairment, referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025, will be included
Key inclusion criteria (2 listed)
- Patients with objective cognitive impairment,
- Referred to our department for a cerebral [¹⁸F]flutemetamol positron emission tomography scan between January 1, 2023 and July 1, 2025,
Key exclusion criteria (1 listed)
- Patient have objected to the use of their data.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol.
Time frame: Day one
Visual analysis of the cerebral [¹⁸F]flutemetamol PET images will be performed by two nuclear medicine specialists in a blinded manner, with a third reader acting as an arbitrator in case of disagreement, according to routine diagnostic criteria.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2026.
Related trials for Alzheimer Disease
RecruitingPhase 1
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
Alzheimer Disease
RecruitingPhase 1
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
Alzheimer s Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
RecruitingObservational study
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
Aging
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Principal Investigator principal investigator
CHRU of NANCY
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Alzheimer Disease, run by Central Hospital, Nancy, France at 3 sites in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Antoine VERGER, MD,PhD (0383155567 ext. +33, a.verger@chru-nancy.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluate the impact of a deep-learning noise reduction algorithm on visual analysis and centiloid quantification when simulating reduced injected doses of 18F-flutemetamol. (time frame: Day one). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2026.